Sotera Health Company posted a Q1 earnings beat this week, reaffirmed its 2026 revenue outlook, and unveiled a CEO transition — yet short interest has climbed more than 50% over the past month, raising an obvious question about what the bears know that the bulls don't.
The short interest picture is the defining tension here. SI hit 5.1% of free float on May 5 — up 52% over 30 days, from roughly 9.5 million shares to 14.6 million. The weekly move was another 5.4% rise, even as Monday's session saw a small pullback. The build has been steady and persistent, starting in early April and accelerating sharply through the final week of that month. At the same time, the ORTEX short score has climbed to 49.7, its highest point in at least two weeks, tracking the underlying accumulation closely. Short sellers have clearly not been deterred by the Q1 numbers.
The borrow market, however, is far from stressed. Availability remains very loose — the lending pool is well supplied, and cost to borrow is just 0.45%, a low figure that has barely moved over the past month despite the jump in shares shorted. Broad availability in the borrow market means new shorts are entering at minimal friction. Options positioning leans bullish rather than defensive: the put/call ratio is only 0.14, above its 20-day average of 0.12 but still very low in absolute terms and well short of any alarm level. Options traders are not hedging aggressively here.
The Street remains constructive, though conviction is slipping. Most analysts hold Overweight or Outperform ratings, with a consensus mean price target around $20.13 — roughly 31% above the current price of $15.33. But targets are moving lower: Piper Sandler trimmed its target from $24 to $22 this week while maintaining Overweight, citing the earnings results. Barclays made a similar cut in April, dropping from $20 to $18 but keeping a positive rating. The pattern is one of gradual confidence erosion rather than outright bearishness — bulls still see value, but the gap between where analysts think the stock should trade and where it actually trades has been a persistent feature of SHC for some time. J.P. Morgan sits more cautiously at Neutral with a $16 target, close to the current price, and that scepticism is consistent with the bear case around regulatory risk, FDA uncertainty, and Nelson Labs margin pressure.
The institutional register adds an interesting wrinkle. The biggest ownership change in the past quarter came from Warburg Pincus and GTCR — both private equity sponsors who sold a combined 25 million shares in a single March block trade at $15.27. Warburg is down to 6.7% of shares outstanding and GTCR to 4.5%, having shed roughly $382 million of stock. That kind of sponsor exit is structurally significant: it removes a longstanding overhang but also raises questions about whether the original owners have finished monetising. Meanwhile, the hedge fund side of the register has been adding — Sculptor, Sessa, and Sachem Head all increased positions meaningfully in the most recent filings, and Voss Capital more than doubled its stake. The activist-friendly structure of the shareholder base is worth tracking.
The most immediate catalyst now shifts to the leadership change. Alton Shader takes over as CEO effective May 26, replacing Michael Petras. The transition was announced alongside the Q1 results, with the company framing it as a planned handover. The next earnings release is scheduled for May 21, five days before the official transition. Piper Sandler's same-day reiteration of Overweight after the management announcement suggests at least some analysts are comfortable with the continuity. But with short interest building aggressively into a CEO change, a full year of sponsor selling still fresh, and a stock priced well below consensus targets, the dynamics going into that May print are worth watching closely.
See the live data behind this article on ORTEX.
Open SHC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
